Year: 2026
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: ABSTRACT Advanced thymic carcinoma is a rare, aggressive malignancy with limited treatment options after chemotherapy failure. This randomized, double‐blind, placebo‐controlled trial (AL3810‐202) aimed to evaluate lucitanib, a novel, orally potent tyrosine kinase inhibitor targeting VEGFR1‒3, FGFR1‒3, and PDGFRα/β in patients with advanced thymic carcinoma progressing after chemotherapy. Sixty‐eight patients were randomized (2:1) to receive 10 mg lucitanib daily ( n = 46) or placebo ( n = 22). Although this study did not meet its primary endpoint of independent review committee (IRC)‐assessed progression‐free survival (PFS) (median 5.8 vs. 3.7 months; hazard ratio [HR]: 0.60; p = 0.1050), the prespecified log‐rank test may have underestimated the treatment effect due to an observed non‐proportional hazards pattern. Subsequent restricted mean survival time analysis demonstrated a statistically significant PFS benefit ( p < 0.05), which was further supported by significantly prolonged investigator‐assessed PFS (6.6 vs. 1.9 months; HR: 0.53; p = 0.0306). The most common grade 3 treatment‐related adverse events (TRAEs) were hypertension (50%), proteinuria (15.2%), and thrombocytopenia (8.7%), with no grade 4/5 events. Considering the totality of the evidence and an acceptable safety profile, lucitanib may confer a meaningful clinical benefit for patients with advanced thymic carcinoma, warranting further investigation.
Source: MedComm
DOI: 10.1002/mco2.71105
Institutions: Tongji University, Shanghai East Hospital, Shanghai Jiao Tong University, Shanghai Chest Hospital, Fudan University Shanghai Cancer Center, Sun Yat-sen University Cancer Center, Union Hospital, Air Force Medical University, Hunan Cancer Hospital, Tianjin Medical University General Hospital, Zhejiang Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital, First Affiliated Hospital Zhejiang University, Capital Medical University, Xuan Wu Hospital of the Capital Medical University, Peking University People's Hospital, First Affiliated Hospital of Zhengzhou University
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,500
OpenAlex ID: W7223560524